Drawing for BIOCEM

USPTO serial 76268881

BIOCEM

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
BROWN, BRIAN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BIOCEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

H. John Camipaign

H JOHN CAMIPAIGN GRAHAM, CAMPAIGN PC3( W 44TH ST STE 1300NEW YORK, NY 10036-8178UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, preparations for the treatment of bone diseases and defectsACTIVE—
010Medical apparatus and instruments, namely, implants for replacement and/or fixation of boneACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 5, 2003ABN1ABANDONMENT - EXPRESS MAILED—
Apr 3, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 17, 2003CNSIINQUIRY AS TO SUSPENSION MAILED—
Jul 2, 2002CNSLLETTER OF SUSPENSION MAILED—
Jul 1, 2002DOCKASSIGNED TO EXAMINER—
Mar 4, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 5, 2001CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 10, 2001DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance